Education
About Us
Working with TipRanks
Follow Us
Spruce Biosciences (SPRB)
NASDAQ:SPRB
Total Valuation
Spruce Biosciences has a market cap or net worth of $111.83M. The enterprise value is -$11.35M.
Market Cap$111.83M
Enterprise Value-$11.35M
Share Statistics
Spruce Biosciences has 1,065,672 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding1,065,672
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Spruce Biosciences’s return on equity (ROE) is -1.84 and return on invested capital (ROIC) is -176.20%.
Return on Equity (ROE)-1.84
Return on Assets (ROA)-1.17
Return on Invested Capital (ROIC)-176.20%
Return on Capital Employed (ROCE)-1.87
Revenue Per Employee245.55K
Profits Per Employee-2.65M
Employee Count20
Asset Turnover0.11
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Spruce Biosciences is ―. Spruce Biosciences’s PEG ratio is -0.00103.
PE Ratio―
PS Ratio0.04
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow-1.18
PEG Ratio-0.00103
Income Statement
In the last 12 months, Spruce Biosciences had revenue of 4.91M and earned -53.04M in profits. Earnings per share was -96.75.
Revenue4.91M
Gross Profit4.91M
Operating Income-56.15M
Pretax Income-53.04M
Net Income-53.04M
EBITDA-52.68M
Earnings Per Share (EPS)-96.75
Cash Flow
In the last 12 months, operating cash flow was -47.55M and capital expenditures 0.00, giving a free cash flow of -47.55M billion.
Operating Cash Flow-47.55M
Free Cash Flow-47.55M
Free Cash Flow per Share-44.62
Dividends & Yields
Spruce Biosciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-10.80
52-Week Price Change161.51%
50-Day Moving Average80.03
200-Day Moving Average30.33
Relative Strength Index (RSI)46.39
Average Volume (3m)988.68K
Important Dates
Spruce Biosciences upcoming earnings date is May 13, 2026, After Close (Confirmed).
Last Earnings DateNov 10, 2025
Next Earnings DateMay 13, 2026
Ex-Dividend Date―
Financial Position
Spruce Biosciences as a current ratio of 2.90, with Debt / Equity ratio of 13.83%
Current Ratio2.90
Quick Ratio2.90
Debt to Market Cap7.95
Net Debt to EBITDA0.68
Interest Coverage Ratio-182.90
Taxes
In the past 12 months, Spruce Biosciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Spruce Biosciences EV to EBITDA ratio is 0.68, with an EV/FCF ratio of 0.64.
EV to Sales-7.28
EV to EBITDA0.68
EV to Free Cash Flow0.64
EV to Operating Cash Flow0.64
Balance Sheet
Spruce Biosciences has $10.67M in cash and marketable securities with $1.04M in debt, giving a net cash position of $9.63M billion.
Cash & Marketable Securities$10.67M
Total Debt$1.04M
Net Cash$9.63M
Net Cash Per Share$9.04
Tangible Book Value Per Share$53.73
Margins
Gross margin is 100.00%, with operating margin of -1143.37%, and net profit margin of -1079.94%.
Gross Margin100.00%
Operating Margin-1143.37%
Pretax Margin-1079.94%
Net Profit Margin-1079.94%
EBITDA Margin-1072.76%
EBIT Margin-1073.69%
Analyst Forecast
The average price target for Spruce Biosciences is $209.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$209.50
Price Target Upside104.99% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-90.18%
EPS Growth Forecast-17.93%